First Amendment to Collaboration and Option AgreementCollaboration and Option Agreement • March 11th, 2020 • ImmunoGen, Inc. • Pharmaceutical preparations
This First Amendment to Collaboration and Option Agreement (this “First Amendment”) is effective as of November 20, 2019 (the “First Amendment Effective Date”) by and between ImmunoGen, Inc., a Massachusetts corporation with its principal place of business at 830 Winter Street, Waltham, Massachusetts 02451 (“ImmunoGen”) and Jazz Pharmaceuticals Ireland Limited, a corporation organized under the laws of Ireland with its principal place of business at Waterloo Exchange, Waterloo Road, Dublin 4, Ireland (“Jazz”), and amends that certain Collaboration and Option Agreement between ImmunoGen and Jazz dated August 28, 2017 (the “Agreement”). ImmunoGen and Jazz may each be referred to individually as a “Party” and collectively as the “Parties”. Capitalized terms not expressly defined herein shall have the meaning set forth in the Agreement.
IMMUNOGEN, INC. PERFORMANCE-BASED NON-QUALIFIED STOCK OPTION TERMS AND CONDITIONSOption Agreement • March 11th, 2020 • ImmunoGen, Inc. • Pharmaceutical preparations • Massachusetts
This Option Agreement is entered into and made effective as of the grant date referenced in the Grant Detail (the “Date of Grant”) and is between ImmunoGen, Inc., a Massachusetts corporation (the “Company”), and the employee or consultant of the Company (the “Participant”) referenced in the Grant Detail. Certain capitalized terms, to the extent not defined where they first appear in this Option Agreement, are defined in the Company’s 2018 Employee, Director and Consultant Equity Incentive Plan (the “Plan”).
